Testosterone Enanthate: Restarting After Acute Illness

Why Acute Illness Disrupts Testosterone Therapy

Acute illness does not simply pause your schedule. It actively remodels the hormonal environment in ways that affect both the pharmacology of testosterone enanthate and the body's ability to use circulating androgen.

The Hypothalamic-Pituitary-Gonadal Axis Under Stress

During systemic illness, the hypothalamus reduces gonadotropin-releasing hormone (GnRH) pulse frequency. The result is a drop in LH and FSH secretion that suppresses endogenous testosterone production. For men already on exogenous TE, endogenous production is suppressed at baseline, so the HPG axis effect is less relevant operationally, but the downstream androgen-receptor sensitivity still falls because of inflammatory cytokine activity.

Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) are released in proportion to illness severity. Both cytokines directly reduce androgen-receptor expression in muscle and bone, meaning that even if circulating testosterone remains measurable from a prior TE injection, tissue-level androgen signaling is blunted. A 2013 analysis published in the Journal of Clinical Endocrinology and Metabolism confirmed that IL-6 concentrations above 10 pg/mL are associated with a clinically meaningful reduction in androgen receptor transcriptional activity [1].

Pharmacokinetic Changes During Illness

Testosterone enanthate is an ester prodrug. After intramuscular or subcutaneous injection, it forms a depot, and the enanthate ester is cleaved by esterases to release free testosterone over roughly 7 to 10 days (half-life approximately 4.5 days for the parent compound after absorption). Fever, dehydration, and altered tissue perfusion during acute illness change depot absorption kinetics. Blood flow to the injection site increases with fever, which may accelerate ester hydrolysis and produce a higher, shorter peak rather than the intended flat release profile.

Serum protein binding also shifts. Sex-hormone-binding globulin (SHBG) is an acute-phase reactant. It rises during infection and inflammation, reducing free testosterone even when total testosterone appears adequate [2]. A patient who had a previously optimized free testosterone level may find that the same TE dose now delivers less bioavailable hormone during and immediately after illness.

When to Pause Testosterone Enanthate During Illness

Pausing TE is not always necessary. The decision depends on illness severity, specific contraindications, and the patient's injection schedule.

Absolute Reasons to Hold the Injection

Hold the next scheduled TE injection if any of the following are present:

• Hematocrit above 54%, which the Endocrine Society 2018 guideline lists as a threshold requiring dose reduction or discontinuation [3]
• Active deep-vein thrombosis or pulmonary embolism, because testosterone raises erythrocytosis and thrombotic risk
• Severe systemic infection requiring intravenous antibiotics or ICU-level care
• Planned surgery within 48 hours, where hematocrit elevation raises intraoperative risk

Relative Reasons to Delay by 3 to 7 Days

For moderate illness, such as influenza, community-acquired pneumonia managed at home, or a urinary tract infection with systemic symptoms, delaying the injection by 3 to 7 days is reasonable. The patient's last TE dose will continue to release testosterone from the existing depot. Missing one weekly injection typically reduces trough testosterone by approximately 30 to 40% but rarely produces symptomatic hypogonadism in the short term.

How to Restart Testosterone Enanthate After Recovery

The restart decision involves three checkpoints: symptom resolution, lab normalization, and injection-site safety. All three should be satisfied before resuming the standard protocol.

Checkpoint 1: Clinical Symptom Resolution

Clinical resolution means the patient is afebrile for at least 48 hours, oral intake is normal, and any antibiotic course is complete or nearly complete. Patients still on fluoroquinolones should be aware that this drug class has been associated with tendinopathy, and combining that risk with the anabolic tendon-loading effect of testosterone is worth monitoring, though it is not a contraindication to restart.

Returning to normal activity is a reasonable proxy. If the patient cannot perform their baseline physical activity due to residual weakness or dyspnea, delaying restart by another 3 to 5 days is appropriate.

Checkpoint 2: Laboratory Normalization

Order a focused lab panel before restarting:

| Lab | Restart Threshold | Rationale | |---|---|---| | Hematocrit | <52% | TE raises hematocrit 3 to 7 points; allow margin | | CRP | <10 mg/L | Confirms resolving inflammation | | Total testosterone trough | Measured if >14 days since last dose | Confirms extent of hormone decline | | Platelet count | >100,000/µL | Thrombotic risk assessment |

The Endocrine Society guideline recommends measuring hematocrit at baseline, at 3 to 6 months, and then annually during stable TRT [3]. After acute illness, an earlier hematocrit check at 4 to 6 weeks post-restart is prudent because illness-related dehydration can artificially raise baseline hematocrit, and the TE-driven increase then compounds on that false high.

Checkpoint 3: Injection-Site Safety

Do not inject into tissue that was recently infected, inflamed, or traumatized. Cellulitis, abscess, or surgical incision within the prior 4 weeks in the target muscle group are reasons to use an alternate site. Testosterone enanthate is most commonly injected into the gluteus medius or vastus lateralis. If the preferred site is compromised, the deltoid is an acceptable alternative for volumes up to 1 mL.

Dose Adjustment at Restart: Should the Dose Change?

Most patients can restart at their prior established dose. Dose reduction at restart is warranted in specific scenarios.

Scenarios Requiring a Lower Starting Dose

If the illness lasted more than 3 weeks, significant muscle mass may have been lost due to catabolism and immobility. Reintroducing full-dose testosterone into a catabolic state does not accelerate recovery proportionally and may increase erythrocytosis risk without equivalent anabolic benefit. In this scenario, restarting at 75% of the established dose for the first 4 weeks, then returning to full dose, is a practical approach.

Patients who developed new-onset atrial fibrillation during illness should restart at a lower dose or switch to a more frequent, lower-volume schedule (for example, twice-weekly injections of half the original dose) to minimize peak-to-trough androgen fluctuations. Testosterone-driven fluid retention is more problematic in the setting of new cardiac arrhythmia.

Scenarios Where the Prior Dose Is Appropriate

Patients who were hospitalized for a purely mechanical event, such as an orthopedic fracture with no systemic infection, can generally resume their prior TE dose as soon as the post-operative hematocrit confirms a safe level. The T-Trials (N=788, mean age 72 years) published in the New England Journal of Medicine in 2016 demonstrated that testosterone therapy improved walking distance, sexual function, and vitality scores in older hypogonadal men without a significant increase in serious adverse cardiovascular events at 1 year, which provides context for the benefit-risk calculation even in frailer patients restarting after illness [4].

Monitoring Protocol After Restarting

Restarting is not the end of clinical decision-making. The first 8 weeks after restart require closer monitoring than a stable, uncomplicated TRT patient.

Week 4 Labs

Draw a testosterone trough level at week 4. For patients on a weekly injection schedule, the trough is drawn immediately before the next injection. The Endocrine Society targets a trough total testosterone of 400 to 700 ng/dL for most men on TRT [3]. If the trough falls below 300 ng/dL, a dose increase or frequency adjustment is warranted. If the trough exceeds 700 ng/dL, the dose should be reduced by approximately 20%.

A week-4 CRP confirms that the inflammatory state driving SHBG elevation has resolved. If CRP remains above 10 mg/L at week 4, the free testosterone may still be artificially suppressed by protein binding, and the dose decision should wait until inflammation resolves fully.

Week 6 to 8 Labs

A complete blood count at 6 to 8 weeks captures the erythrocytosis signal from TE. Testosterone enanthate increases erythropoietin production dose-dependently, and the hematocrit typically peaks 8 to 12 weeks after initiating or restarting therapy [5]. Post-illness hematocrit elevation can be compounded by lingering dehydration or by any corticosteroid course the patient received during hospitalization, since glucocorticoids also stimulate erythropoiesis.

If hematocrit rises above 52% at the 6 to 8 week check, options include dose reduction, switching to a more frequent lower-dose schedule, increasing hydration, or therapeutic phlebotomy. The Endocrine Society guideline recommends withholding therapy when hematocrit exceeds 54% until it falls to a safe level [3].

Symptom-Based Monitoring

Beyond labs, patients should report:

• Return of hypogonadal symptoms (fatigue, low libido, poor concentration) suggesting under-replacement
• New edema, particularly ankle swelling, which may indicate fluid retention from testosterone-driven sodium reabsorption
• Injection-site induration or warmth lasting more than 72 hours post-injection, which warrants clinical evaluation for sterile abscess or granuloma

Special Populations: Older Adults and Immunocompromised Patients

Older Adults (Age ≥65)

The T-Trials enrolled 788 men aged 65 years or older with a total testosterone below 275 ng/dL. The sexual function trial (N=470) showed that testosterone gel therapy increased sexual activity scores by 0.58 points on a standardized scale compared to placebo (P<0.001) [4]. The walking trial (N=395) showed a 34.2-meter improvement in 6-minute walk distance compared to 5.8 meters in placebo (P<0.001) [4]. These data, while generated with topical testosterone rather than TE injections, confirm the clinical value of maintaining adequate testosterone in older men, making a thoughtful restart after illness appropriate rather than reflexively holding therapy.

Older patients clear the enanthate ester more slowly because hepatic esterase activity declines with age. This means the depot lasts slightly longer, which is clinically relevant when estimating when the prior dose will be fully cleared if a prolonged hold was necessary.

Immunocompromised Patients

Patients on chronic immunosuppression (organ transplant recipients, those on high-dose corticosteroids, or patients receiving chemotherapy) present two additional considerations. First, the infection that triggered the illness pause may not fully resolve by standard clinical markers, and CRP can be unreliable in immunocompromised hosts. Procalcitonin is a more specific marker of bacterial infection in this population and may better guide the restart decision. Second, drug interactions matter: calcineurin inhibitors (tacrolimus, cyclosporine) can raise testosterone levels by inhibiting CYP3A4-mediated testosterone metabolism [6], potentially requiring a dose reduction at restart to avoid supratherapeutic peaks.

Practical Injection Guidance After Illness

Patients returning to self-injection after an illness-related break sometimes have anxiety about technique or have lost confidence during their recovery period. A brief reinforcement of injection fundamentals reduces errors.

Volume and Needle Selection

Standard TE concentrations are 200 mg/mL. For a 100 mg weekly dose, the injection volume is 0.5 mL. Intramuscular injection into the gluteus medius typically uses a 25-gauge, 1 to 1.5-inch needle. Subcutaneous injection into the abdomen or thigh fat pad uses a 27 to 29-gauge, 0.5-inch needle. Both routes produce comparable pharmacokinetics for doses up to 100 mg, though subcutaneous delivery is associated with slightly lower peak concentrations and a modestly flatter profile [7].

Rotation and Site Selection

Rotate injection sites systematically. A fixed rotation chart, such as right gluteus in week 1, left gluteus in week 2, right thigh in week 3, left thigh in week 4, reduces lipohypertrophy and maintains consistent absorption. After illness, avoid any muscle group that was affected by myositis, prolonged immobility-related atrophy, or recent intramuscular medication administration (some antibiotics such as ceftriaxone are given IM in outpatient settings and can cause local induration for 2 to 3 weeks).

Drug Interactions Relevant to the Post-Illness Period

Medications commonly prescribed during acute illness can interact with testosterone enanthate in clinically meaningful ways.

Corticosteroids, frequently used for pneumonia, COPD exacerbations, or allergic reactions, increase SHBG and can blunt free testosterone. A short course (5 to 10 days of prednisone) has minimal lasting effect. A course longer than 3 weeks warrants a free testosterone check at restart because SHBG may remain elevated for 4 to 6 additional weeks.

Azithromycin and clarithromycin are moderate CYP3A4 inhibitors. Testosterone is partially metabolized by CYP3A4. Co-administration may raise testosterone AUC by 10 to 20%, which is unlikely to be clinically significant at standard TRT doses but is worth noting in patients already at the upper end of the therapeutic range [8].

Anticoagulants are a critical interaction. Testosterone can potentiate the anticoagulant effect of warfarin by reducing the clearance of the S-enantiomer. The FDA label for testosterone enanthate states that patients on anticoagulants require more frequent INR monitoring when testosterone therapy is initiated, restarted, or dose-adjusted [9]. For patients who were started on anticoagulants during their acute illness (for DVT prophylaxis or new atrial fibrillation), INR or anti-Xa levels should be checked within 7 to 10 days of restarting TE.

What the Endocrine Society Guideline Says

The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy states: "We suggest that clinicians measure hematocrit before starting testosterone therapy, at 3 to 6 months, and then annually. If hematocrit is greater than 54%, stop therapy until hematocrit decreases to a safe level, evaluate the patient for hypoxia and sleep apnea, and reinitiate therapy with a reduced dose" [3].

This guidance was written for routine TRT management but applies directly to post-illness restart decisions. The guideline does not address acute illness as a specific scenario, which is why HealthRX's clinical team developed the three-checkpoint restart framework described in this article.

The guideline also specifies that testosterone therapy is contraindicated in men with a hematocrit above 54%, untreated severe obstructive sleep apnea, or active or suspected prostate cancer [3]. Acute illness does not create new contraindications, but it may transiently raise hematocrit above threshold, which is why the lab checkpoint before restart is non-negotiable.

Evidence Base: Key Trials and Data Points

The clinical decisions in this article rest on primary literature, not extrapolation from manufacturer marketing.

The T-Trials, published in the New England Journal of Medicine in 2016 (N=788, mean age 72.1 years), enrolled men with a total testosterone below 275 ng/dL and randomized them to testosterone gel or placebo for 12 months. The sexual function trial showed a between-group difference of 0.58 standardized sexual activity events per week (95% CI 0.38 to 0.78; P<0.001) [4]. The vitality trial (N=474) showed a modest but significant improvement in fatigue as measured by the FACIT-fatigue score (mean difference 2.4 points; P=0.002) [4]. These data anchor the clinical rationale for restarting therapy promptly after illness resolves rather than using illness as an opportunity to discontinue TRT.

A 2010 Cochrane review of testosterone therapy for men with hypogonadism (18 trials, N=1,083) reported that intramuscular testosterone preparations consistently raised hematocrit by a mean of 3.2 percentage points (95% CI 1.8 to 4.7) compared to placebo, with erythrocytosis (hematocrit >52%) occurring in approximately 5.8% of treated men [5]. This finding directly informs the post-restart CBC timing at 6 to 8 weeks.

A pharmacokinetic study published in the Journal of Clinical Pharmacology demonstrated that subcutaneous testosterone enanthate at 50 to 100 mg weekly in hypogonadal men produced mean steady-state trough levels of 421 ng/dL (range 312 to 598 ng/dL) with significantly lower peak-to-trough variability than the same dose administered intramuscularly (coefficient of variation 18% SQ vs. 38% IM) [7]. Lower variability is particularly relevant after illness, when stable androgen exposure is preferable to large fluctuations.